Organovo Holdings Overview
Organovo Holdings (ONVO) has a ROE of 525.92%, above the Healthcare sector average of 20.77%.
Get informed when a big investor buys or sells
+ Follow525.92%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for ONVO is 525.92%. That is above the Healthcare sector average of 20.77%. Investors often review this figure alongside Organovo Holdings's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ONVO currently prints 525.92% for ROE, while the sector average sits near 20.77%. That is roughly 2432.6% above the sector mean. Large gaps often invite a closer look at Organovo Holdings's growth, margins, and balance sheet.
Return on Equity shows how effectively Organovo Holdings converts resources into returns. At 525.92%, ONVO may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting ONVO's ROE (525.92%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Organovo Holdings's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
